Literature DB >> 29374796

Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial.

Wenying Fan1,2,3, Nizar Saleh Abdelfattah1,2, Akihito Uji1,2, Jianqin Lei1,2, Michael Ip1,2, SriniVas R Sadda4,5, Charles C Wykoff6,7.   

Abstract

BACKGROUND: Our purpose was to evaluate the relationship between subfoveal choroidal thickness (SCT) and development of macular atrophy (MA) in eyes with age-related macular degeneration (AMD).
METHODS: This was a prospective, multicenter study. Sixty participants (120 eyes) in the TREX-AMD trial (NCT01648292) with treatment-naïve neovascular AMD (NVAMD) in at least one eye were included. SCT was measured by certified reading center graders at baseline using spectral domain optical coherence tomography (SDOCT). The baseline SCT was correlated with the presence of MA at baseline and development of incident MA by month 18. Generalized estimating equations were used to account for information from both eyes.
RESULTS: Baseline SCT in eyes with MA was statistically significantly less than in those without MA in both the dry AMD (DAMD) (P = 0.04) and NVAMD (P = 0.01) groups. Comparison of baseline SCT between MA developers and non-MA developers revealed a statistically significant difference (P = 0.03). Receiver operating characteristic curve (ROC) analysis showed the cut-off threshold of SCT for predicting the development of MA in cases without MA at baseline was 124 μm (AUC = 0.772; Sensitivity = 0.923; Specificity = 0.5). Among eyes without MA at baseline, those with baseline SCT ≤124 μm were 4.3 times more likely to develop MA (Odds ratio: 4.3, 95% confidence interval: 1.6-12, P = 0.005) than those with baseline SCT >124 μm.
CONCLUSIONS: Eyes with AMD and MA had less SCT than those without MA. Eyes with less baseline SCT also appear to be at higher risk to develop MA within 18 months.

Entities:  

Keywords:  Age-related macular degeneration; Choroidal thickness; Macular atrophy; Neovascular age-related macular degeneration; Treat-and-extend

Mesh:

Substances:

Year:  2018        PMID: 29374796     DOI: 10.1007/s00417-017-3888-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  5 in total

1.  Choroidal thickness changes in children with chronic heart failure due to dilated cardiomyopathy.

Authors:  Klaudia Rakusiewicz; Krystyna Kanigowska; Wojciech Hautz; Lidia Ziółkowska
Journal:  Int Ophthalmol       Date:  2021-05-09       Impact factor: 2.031

Review 2.  An evidence-based approach to the routine use of optical coherence tomography.

Authors:  Angelica Ly; Jack Phu; Paula Katalinic; Michael Kalloniatis
Journal:  Clin Exp Optom       Date:  2018-12-17       Impact factor: 2.742

3.  Enlargement rate of geographic atrophy before and after secondary CNV conversion with associated anti-VEGF treatment.

Authors:  Jakob Siedlecki; Caroline Koch; Benedikt Schworm; Raffael Liegl; Thomas Kreutzer; Karsten U Kortuem; Ricarda Schumann; Siegfried G Priglinger; Armin Wolf
Journal:  BMC Ophthalmol       Date:  2021-01-05       Impact factor: 2.209

4.  Increased Systemic C-Reactive Protein Is Associated With Choroidal Thinning in Intermediate Age-Related Macular Degeneration.

Authors:  Rachel C Chen; Alan G Palestine; Anne M Lynch; Jennifer L Patnaik; Brandie D Wagner; Marc T Mathias; Naresh Mandava
Journal:  Transl Vis Sci Technol       Date:  2021-10-04       Impact factor: 3.283

Review 5.  A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II.

Authors:  Mania Horani; Sajjad Mahmood; Tariq M Aslam
Journal:  Ophthalmol Ther       Date:  2020-01-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.